YahooOctober 13, 2026 at 10:12 AM NY14 Days Ago
What Could Bristol Myers Squibb (BMY) Two Phase 3 Wins Change?
Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 data for admilparant in idiopathic pulmonary fibrosis and RYZ101 in gastroenteropancreatic neuroendocrine tumors. Admilparant showed significant clinical benefits and a favorable safety profile in idiopathic pulmonary fibrosis, targeting a serious chronic lung disease. RYZ101 improved progression free survival in patients with gastroenteropancreatic neuroendocrine tumors, supporting upcoming regulatory discussions. The Phase 3 wins...
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
